Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 243 followers
Latest posts
Last updated 4 days ago
Lilly to participate in TD Cowen's 45th Annual Health Care Conference
4 days ago
INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
15 days ago
More than 90% of Omvoh-treated patients who were in clinical remission at...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
15 days ago
More than 90% of Omvoh-treated patients who were in clinical remission at...
Lilly reports full Q4 2024 financial results and provides 2025 guidance
16 days ago
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume...
Lilly reports full Q4 2024 financial results and provides 2025 guidance
16 days ago
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume...
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
30 days ago
INDIANAPOLIS , Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
30 days ago
INDIANAPOLIS , Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
about 1 month ago
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
about 1 month ago
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
about 1 month ago
2024 revenue is expected to be approximately $45.0 billion for the full...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
about 1 month ago
2024 revenue is expected to be approximately $45.0 billion for the full...
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
about 1 month ago
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and...